TrialSite has chronicled the ivermectin studies, including the important PRINCIPLE trial led by the University of Oxford. Now, interestingly, the prestigious Anglo-academic research center has announced the ivermectin arm of the study is on “hold” due to “temporary supply issues.”
Marty Makary’s MedPage Today did some digging Ivermectin Arm of PRINCIPLE Trial Put on Hold | MedPage Today into the matter. Jennifer Henderson, an investigative writer, shared that Merck, a key producer of the generic typically available drug, didn’t comment to the medical news online media.
Noteworthy, Ms. Henderson and MedPage Today interestingly first turned to Merck and the New Jersey-based pharmaceutical company’s point of view as a sort of appeal to an authority. Merck’s response could be interpreted as a signal of the drug’s fate as a possible COVID-19 treatment candidate: the company “concluded that the probability of ivermectin providing a potentially safe and efficacious treatment option for SARS-CoV-2 infection is low and has prioritized internal efforts towards the development of alternate candidates that provide a higher probability of success for the treatment of COVID-19.”
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).